Adial Pharmaceuticals Announces Positive Pre-Clinical Data for PNV2 as a Drug Candidate for Triple Negative Breast Cancer

NEXT STORY
Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma
PREV STORY
Omicron Variant Underscores Need for New COVID Vaccine Candidates Like IBIO-202
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Vical to Provide Company Update at BIO Asia International Conference

SAN DIEGO, March 09, 2017 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that ...

author_avatar
NASDAQ Market News

Leap Therapeutics Presents Non-clinical and Phase 1 Data for TRX518 and DKN-01 at the 2017 AACR Annual Meeting

CAMBRIDGE, Mass., April 03, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology ...

author_avatar
NASDAQ Market News

Aptevo Therapeutics Presents New Patient-Reported Data With IXINITY

Data Presented at the Thrombosis and Hemostasis 2018 Summit of North America SEATTLE, March ...

author_avatar
NASDAQ Market News